Antibody Directed Phototherapy for Oesophageal Adenocarcinoma

食管腺癌抗体定向光疗

• 批准号: 101444
• 金额: $ 82.28万
• 依托单位: ANTIKOR BIOPHARMA LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2013
• 资助国家: 英国
• 起止时间: 2013 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=101444
• 关键词: Antibody; Directed; Phototherapy; Oesophageal; Adenocarcinoma

Oesophageal Cancer is rapidly rising and is the 4th largest cancer killer in men. This project supports combining PhotoBiotics' proprietary OptiLink technology and its own drugs with experts from Imperial College and University College London National Medical Laser Centre to develop a novel antibody-directed phototherapy (ADP) drug to treat cancer. These drugs have few side effects and tumours cannot develop drug resistance to them. We have identified a clinically-validated target and have preliminary data to show that we can tackle this for Oesophageal Cancer. Photobiotics will oversee the manufacture and testing of the drug, Imperial College will help to generate functional data and UCL will treat tumours using their established models. If successful, thus funding will lead to major interest from the pharmaceutical industry to take this into clinical trials.

食道癌正在迅速上升，是男性第四大癌症杀手。该项目支持将 PhotoBiotics 的专有 OptiLink 技术及其自有药物与帝国理工学院和伦敦大学学院国家医学激光中心的专家相结合，开发一种新型抗体导向光疗 (ADP) 药物来治疗癌症。这些药物副作用很少，肿瘤不会对其产生耐药性。我们已经确定了一个经过临床验证的目标，并有初步数据表明我们可以解决食道癌的这一问题。 Photobiotics 将监督该药物的制造和测试，帝国理工学院将帮助生成功能数据，伦敦大学学院将使用其已建立的模型治疗肿瘤。如果成功，资金将引起制药行业的极大兴趣，将其纳入临床试验。